Login to Your Account

Karo Bio Eyes 2011 Start for Eprotirome Pivotal Program

By Cormac Sheridan

Wednesday, September 1, 2010
Karo Bio AB is finalizing the design of a Phase III program for its lead drug candidate, eprotirome (KB2115), which is in development for heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by the accumulation of elevated levels of low density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis at an early age. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription